Comparative Pharmacology
Head-to-head clinical analysis: NYDRAZID versus POTASSIUM AMINOSALICYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYDRAZID versus POTASSIUM AMINOSALICYLATE.
NYDRAZID vs POTASSIUM AMINOSALICYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
None Documented
None Documented
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent